We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
+15.26%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$125M
AUM Growth
-$37.3M
Cap. Flow
-$58.8M
Cap. Flow %
-47.11%
Top 10 Hldgs %
46.07%
Holding
88
New
6
Increased
20
Reduced
44
Closed
14

Top Buys

Rank Stock Value
1
EVMN
Evommune Inc
EVMN
+$11.1M
2
LENZ
LENZ Therapeutics
LENZ
+$1.24M
3
JNJ icon
Johnson & Johnson
JNJ
+$989K
4
COGT icon
Cogent Biosciences
COGT
+$919K
5
AMGN icon
Amgen
AMGN
+$866K

Top Sells

Rank Stock Value
1
GPCR icon
Structure Therapeutics
GPCR
+$8.08M
2
VTYX
Ventyx Biosciences
VTYX
+$7.55M
3
RCUS icon
Arcus Biosciences
RCUS
+$6.35M
4
ANAB icon
AnaptysBio
ANAB
+$5.96M
5
IMTX icon
Immatics
IMTX
+$5.02M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMTX icon
51
Immatics
IMTX
$1.18B
$662K 0.53%
63,015
-497,479
-89% -$5.02M
HNGE
52
Hinge Health
HNGE
$5.78B
$660K 0.53%
14,206
+3,000
+27% +$144K
BMRN icon
53
BioMarin Pharmaceuticals
BMRN
$11.6B
$647K 0.52%
10,880
-14,150
-57% -$770K
ALHC icon
54
Alignment Healthcare
ALHC
$3.08B
$622K 0.5%
31,500
-23,000
-42% -$413K
FOLD
55
DELISTED
Amicus Therapeutics
FOLD
$617K 0.49%
43,300
-75,805
-64% -$745K
PRVA icon
56
Privia Health
PRVA
$2.98B
$616K 0.49%
26,000
-10,500
-29% -$256K
CARL
57
Carlsmed
CARL
$342M
$589K 0.47%
+47,700
New +$635K
PTCT icon
58
PTC Therapeutics
PTCT
$5.68B
$586K 0.47%
7,715
-820
-10% -$59.6K
OMDA
59
Omada Health Inc
OMDA
$1.18B
$576K 0.46%
36,500
+9,000
+33% +$183K
NKTR icon
60
Nektar Therapeutics
NKTR
$2.39B
$570K 0.46%
+13,485
New +$755K
KURA icon
61
Kura Oncology
KURA
$800M
$562K 0.45%
54,110
-341,762
-86% -$3.59M
NBIX icon
62
Neurocrine Biosciences
NBIX
$16.8B
$379K 0.3%
2,675
-285
-10% -$41.3K
BIIB icon
63
Biogen
BIIB
$30B
$379K 0.3%
2,155
-220
-9% -$35.9K
CYTK icon
64
Cytokinetics
CYTK
$10.5B
$374K 0.3%
5,893
-4,330
-42% -$269K
JAZZ icon
65
Jazz Pharmaceuticals
JAZZ
$15.9B
$348K 0.28%
2,049
-195
-9% -$29.9K
SPRY icon
66
ARS Pharmaceuticals
SPRY
$509M
$347K 0.28%
29,803
-51,982
-64% -$506K
RPRX icon
67
Royalty Pharma
RPRX
$25.9B
$327K 0.26%
8,470
-810
-9% -$30.9K
ILMN icon
68
Illumina
ILMN
$31B
$324K 0.26%
2,472
-255
-9% -$29.9K
AXSM icon
69
Axsome Therapeutics
AXSM
$11.2B
$318K 0.25%
1,740
+720
+71% +$101K
INCY icon
70
Incyte
INCY
$24.2B
$272K 0.22%
2,750
-280
-9% -$27.1K
TEM
71
Tempus AI
TEM
$7.92B
$266K 0.21%
4,500
+740
+20% +$57.9K
MDGL icon
72
Madrigal Pharmaceuticals
MDGL
$10.8B
$205K 0.16%
352
-378
-52% -$193K
ORIC icon
73
Oric Pharmaceuticals
ORIC
$1.15B
$184K 0.15%
22,480
-306,175
-93% -$3.52M
MRNA icon
74
Moderna
MRNA
$21.8B
$148K 0.12%
5,005
-595
-11% -$16.2K
ANAB icon
75
AnaptysBio
ANAB
$1.58B
– –
-194,485
Closed -$5.96M
1 2
3
4

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
AAA
AG Asset Advisory Los Angeles, California $121M AUM 10.78% 1-Year Est. Return
TGM
Tenzing Global Management San Francisco, California $121M AUM 85.62% 1-Year Est. Return

Sectoral Asset Management's Q4 2025 Portfolio in Review

As of Q4 2025, Sectoral Asset Management held 88 positions worth $125M, down 23% from $162M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Sectoral Asset Management withdrew a net $58.8M in Q4 2025, closing 14 positions and reducing 44 holdings. Its most notable exit was AnaptysBio, an estimated $5.96M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

Against the trend, Sectoral Asset Management opened a new position in Evommune Inc worth $10.1M.

  • Sectoral Asset Management's largest Q4 2025 buy was Evommune Inc: 589,005 shares worth $10.1M.
  • Sectoral Asset Management added most to Johnson & Johnson in Q4 2025, an estimated $989K increase.
  • Sectoral Asset Management's biggest Q4 2025 reduction was Structure Therapeutics, cutting an estimated $8.08M.
  • Sectoral Asset Management fully exited AnaptysBio in Q4 2025, selling an estimated $5.96M.
  • Sectoral Asset Management's ten largest holdings make up 46% of its $125M portfolio in Q4 2025.
  • Sectoral Asset Management opened 6 new positions and closed 14 in Q4 2025.
  • Sectoral Asset Management's portfolio value fell 23% quarter-over-quarter to $125M.

Based on Sectoral Asset Management's 13F filing for Q4 2025, filed 9 Feb 2026.